B

Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315

Watchlist Manager
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Watchlist
Price: 8.25 HKD -2.02% Market Closed
Market Cap: 3.3B HKD
Have any thoughts about
Biocytogen Pharmaceuticals Beijing Co Ltd?
Write Note

Biocytogen Pharmaceuticals Beijing Co Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biocytogen Pharmaceuticals Beijing Co Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
B
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Total Liabilities & Equity
ÂĄ2.4B
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Liabilities & Equity
ÂĄ41.1B
CAGR 3-Years
4%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Liabilities & Equity
ÂĄ20.3B
CAGR 3-Years
7%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Liabilities & Equity
ÂĄ15.7B
CAGR 3-Years
65%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Liabilities & Equity
ÂĄ54.8B
CAGR 3-Years
26%
CAGR 5-Years
38%
CAGR 10-Years
36%
Imeik Technology Development Co Ltd
SZSE:300896
Total Liabilities & Equity
ÂĄ6.9B
CAGR 3-Years
14%
CAGR 5-Years
71%
CAGR 10-Years
N/A
No Stocks Found

Biocytogen Pharmaceuticals Beijing Co Ltd
Glance View

Market Cap
3.3B HKD
Industry
Biotechnology

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. The company is headquartered in Beijing, Beijing. The company went IPO on 2022-09-01. The firm operates two business segments. The Drug Development Business segment is mainly engaged in the research and development of oncology and autoimmune disease treatments, as well as antibody development. The Preclinical Research Service segment is mainly engaged in gene editing, preclinical pharmacological efficacy evaluation and model animal sales.

Intrinsic Value
11.01 HKD
Undervaluation 25%
Intrinsic Value
Price
B

See Also

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
2.4B CNY

Based on the financial report for Dec 31, 2023, Biocytogen Pharmaceuticals Beijing Co Ltd's Total Liabilities & Equity amounts to 2.4B CNY.

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 3Y
2%

Over the last year, the Total Liabilities & Equity growth was -13%. The average annual Total Liabilities & Equity growth rates for Biocytogen Pharmaceuticals Beijing Co Ltd have been 2% over the past three years .

Back to Top